Key terms
About SNY
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest SNY news
Today
12:26am ET
Maintaining Buy Rating on Sanofi: A Resilient Financial Outlook Despite Currency Headwinds
Apr 11
4:46pm ET
Meet First Wave BioPharma: Exclusive interview with CEO James Sapirstein
Apr 05
5:53am ET
Sanofi announces launch of Verorab in UK
Apr 04
9:35am ET
Barclays Sticks to Its Buy Rating for Sanofi (SNYNF)
Apr 03
4:57pm ET
Sanofi to resolve roughly 5,000 Zantac lawsuits in U.S., Bloomberg says
Mar 27
6:36am ET
Dr. Reddy’s enters partnership with Sanofi to distribute vaccines in India
Mar 27
6:25am ET
AstraZeneca, Sanofi announce Beyfortus approved in Japan
Mar 27
6:16am ET
Annexon price target raised to $12 from $11 at Wells Fargo
Mar 20
2:57pm ET
Sanofi’s Amlitelimab Shows Lasting Benefits
Mar 19
1:36am ET
Sanofi’s Buy Rating Affirmed by Analyst on Strong Clinical Trials and Market Opportunities
Mar 13
11:00am ET
European Stocks: Unnoticed Records, Overlooked Opportunities
Mar 11
6:29am ET
Sanofi reports ‘positive’ results from Part 2 of STREAM-AD study
Mar 04
8:48am ET
Sanofi price target lowered to EUR 114 from EUR 120 at Guggenheim
Feb 28
7:39pm ET
Inhibrx downgraded to Hold from Buy at Jefferies
Feb 25
3:23pm ET
Sanofi reports ‘positive’ results from Phase 2 RILECSU study
Feb 23
5:16am ET
Regeneron, Sanofi announce FDA acceptance for priority review of Dupixent sBLA
Feb 21
6:19am ET
Sanofi’s RSV shot had a bumpy rollout, more popular than expected, WSJ says
Feb 20
9:27am ET
Sanofi consumer health unit seeing intertest ahead of split, Bloomberg says
Feb 20
9:27am ET
Sanofi consumer health unit seeing intertest ahead of split, Bloomberg says
Feb 20
8:59am ET
Denali Therapeutics ALS study failue ‘clearing event,’ says B. Riley
Feb 20
8:55am ET
Denali continues decline after Sanofi ALS study failure
Feb 16
5:26am ET
Regeneron, Sanofi announce MHLW in Japan approves Dupixent
Feb 15
8:22am ET
Sanofi reports Phase 2 data on frexalimab published in NEJM
Feb 15
8:09am ET
Sanofi announces Phase 2 data published in NEJM on frexalimab
Feb 14
4:12pm ET
Dianthus initiated with a Buy at Stifel
Feb 12
4:42pm ET
Sanofi price target raised to EUR 94 from EUR 92 at JPMorgan
Feb 07
8:27am ET
Sanofi Growth Prospects and Pipeline Potential Affirm Buy Rating
Feb 06
8:35am ET
Deutsche Bank Sticks to Its Sell Rating for Sanofi (SNYNF)
Feb 05
8:52am ET
Regeneron price target raised to $1,110 from $1,076 at RBC Capital
Feb 05
7:35am ET
DZ BANK AG Remains a Hold on Sanofi (SNYNF)
Feb 05
6:35am ET
UBS Sticks to Their Buy Rating for Sanofi (SNYNF)
No recent press releases are available for SNY
SNY Financials
Key terms
Ad Feedback
SNY Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
SNY Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range